← The Wire
ROIVNasdaq
Roivant Sciences Ltd.
Pharmaceutical Preparations · D0 · CIK 1635088
Roivant Sciences Ltd. accelerates the development and commercialization of medicines through nimble subsidiaries
$21.61B
Market cap
$34.73
Last close
+1.9%
1D
+11.1%
5D
6.4M
Volume
Price · last 39 sessions+22.5%
May 4L $28.21 · H $34.73Jun 29
141
Total filings
May 20, 2026
Last filing
03/31
Fiscal year end
10-K10-KMay 20, 20268-KResults of OperationsMay 20, 20268-KResults of Operations · Reg FD DisclosureApr 2, 20268-K/AMaterial AgreementMar 23, 20268-KMaterial Agreement · Reg FD DisclosureMar 3, 20268-KReg FD DisclosureMar 3, 202610-Q10-QFeb 6, 20268-KResults of OperationsFeb 6, 20268-KReg FD DisclosureDec 11, 202510-Q10-QNov 10, 20258-KResults of OperationsNov 10, 20258-KReg FD Disclosure · Company UpdateSep 17, 20258-KShareholder VoteSep 11, 20258-KReg FD Disclosure · Company UpdateSep 3, 202510-Q10-QAug 11, 20258-KResults of OperationsAug 11, 2025DEF 14ADEF 14AJul 29, 2025DEFA14ADEFA14AJul 29, 20258-KCompany UpdateJun 25, 202510-K10-KMay 29, 20258-KResults of OperationsMay 29, 20258-KReg FD DisclosureApr 21, 20258-KExecutive ChangeMar 20, 20258-KReg FD Disclosure · Company UpdateMar 19, 20258-KExecutive ChangeFeb 21, 202510-Q10-QFeb 10, 20258-KResults of OperationsFeb 10, 20258-KReg FD DisclosureDec 3, 2024SC 13GSC 13GNov 12, 202410-Q10-QNov 12, 20248-KResults of OperationsNov 12, 2024SC 13GSC 13GNov 8, 20248-KAgreement Terminated · Reg FD DisclosureOct 28, 2024SC 13GSC 13GOct 24, 20248-KMaterial AgreementSep 23, 20248-KReg FD DisclosureSep 18, 20248-KShareholder VoteSep 16, 20248-KReg FD DisclosureSep 10, 20248-KReg FD DisclosureSep 9, 202410-Q10-QAug 9, 20248-KResults of OperationsAug 8, 2024DEFA14ADEFA14AJul 26, 2024DEF 14ADEF 14AJul 26, 202410-K10-KMay 30, 20248-KMaterial AgreementMay 30, 20248-KResults of OperationsMay 30, 20248-KCompany UpdateApr 2, 202410-Q10-QFeb 13, 20248-KResults of OperationsFeb 13, 20248-KReg FD Disclosure · Company UpdateDec 20, 20238-K/ACompany UpdateDec 20, 20238-KAcquisition / Disposition · Company UpdateDec 14, 20238-KCompany UpdateNov 28, 20238-KCompany UpdateNov 27, 202310-Q10-QNov 13, 20238-KResults of OperationsNov 13, 20238-KMaterial Agreement · Company UpdateOct 23, 2023424B5424B5Oct 6, 20238-KMaterial AgreementSep 29, 2023424B5424B5Sep 26, 20238-KCompany UpdateSep 26, 20238-KShareholder VoteSep 15, 20238-KCompany UpdateSep 11, 20238-KCompany UpdateAug 17, 202310-Q10-QAug 14, 20238-KResults of OperationsAug 14, 20238-KExecutive ChangeAug 4, 20238-KCompany UpdateAug 2, 2023DEFA14AFORM DEFA14AJul 31, 2023DEF 14ADEF 14AJul 31, 20238-K/AResults of OperationsJun 28, 202310-K10-KJun 28, 20238-KResults of OperationsJun 28, 20238-KCompany UpdateJun 22, 20238-KCompany UpdateMay 16, 20238-KCompany UpdateApr 4, 20238-KExecutive ChangeMar 16, 20238-KCompany UpdateMar 15, 20238-KExecutive ChangeFeb 21, 202310-Q10-Q.Feb 13, 2023
Insider Activity
In the 90 days to Mar 26, 2026: 8 sold $236.4M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 26, 2026 | Fitzgerald MeghanDirector | Sell | 70,000 | $27.45 | $1.9M |
| Mar 17, 2026 | Venker EricPresident & Immunovant CEO | Sell | 200,000 | $28.24 | $5.6M |
| Mar 16, 2026 | Epperly Melissa B,Director | Sell | 41,861 | $28.68 | $1.2M |
| Feb 23, 2026 | Torti FrankPresident and Vant Chair | Sell | 587,390 | $27.51 | $16.2M |
| Feb 20, 2026 | Torti FrankPresident and Vant Chair | Sell | 1,012,610 | $27.15 | $27.5M |
| Feb 19, 2026 | Torti FrankPresident and Vant Chair | Sell | 1,400,000 | $27.42 | $38.4M |
| Feb 13, 2026 | Manchester Keith SDirector | Sell | 225,000 | $26.50 | $6.0M |
| Feb 13, 2026 | Gold Daniel AllenDirector | Sell | 225,000 | $26.50 | $6.0M |
| Feb 13, 2026 | Qvt Financial LpOther | Sell | 225,000 | $26.50 | $6.0M |
| Feb 13, 2026 | Venker EricPresident & Immunovant CEO | Sell | 200,000 | $26.49 | $5.3M |
| Feb 13, 2026 | Qvt Financial LpOther | Sell | 150,784 | $26.49 | $4.0M |
| Feb 13, 2026 | Manchester Keith SDirector | Sell | 150,784 | $26.49 | $4.0M |
| Feb 13, 2026 | Gold Daniel AllenDirector | Sell | 150,784 | $26.49 | $4.0M |
| Feb 12, 2026 | Gold Daniel AllenDirector | Sell | 275,000 | $26.76 | $7.4M |
| Feb 12, 2026 | Manchester Keith SDirector | Sell | 275,000 | $26.76 | $7.4M |
| Feb 12, 2026 | Qvt Financial LpOther | Sell | 275,000 | $26.76 | $7.4M |
| Feb 12, 2026 | Gold Daniel AllenDirector | Sell | 150,000 | $26.72 | $4.0M |
| Feb 12, 2026 | Qvt Financial LpOther | Sell | 150,000 | $26.72 | $4.0M |
| Feb 12, 2026 | Manchester Keith SDirector | Sell | 150,000 | $26.72 | $4.0M |
| Feb 11, 2026 | Gold Daniel AllenDirector | Sell | 425,000 | $26.67 | $11.3M |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
In the News
Barron's2 Biotech Stocks Are Surging Today Thanks to This Arthritis Drug1mo agoInvestor's Business DailyThese Two Biotech Stocks Rocketed — And One Just Broke Out1mo ago
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
Similar companies
Comparable business profile · signals at a glance